Literature DB >> 17585318

Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma.

Ling Cen1, Kristy J Arnoczky, Fu-Chuan Hsieh, Huey-Jen Lin, Stephen J Qualman, Songlin Yu, Huiyun Xiang, Jiayuh Lin.   

Abstract

Rhabdomyosarcoma is the most common pediatric soft-tissue sarcoma, which includes two major subtypes, alveolar and embryonal rhabdomyosarcoma. The mechanism of its oncogenesis is largely unknown. However, the oncogenic process of rhabdomyosarcoma involves multi-stages of signaling protein dysregulation characterized by prolonged activation of tyrosine and serine/threonine kinases. To better understand this protein dysregulation, we evaluated the phosphorylation profiles of multiple tyrosine and serine/threonine kinases to identify whether these protein kinases are activated in rhabdomyosarcoma. We applied immunohistochemistry with phospho-specific antibodies to examine phosphorylation levels of selected receptor and non-receptor tyrosine kinases, mammalian target of rapamycin (mTOR), p70S6K, and protein kinase C (PKC) isozymes on alveolar and embryonal rhabdomyosarcoma tissue microarray slides. Our results showed that the phosphorylation levels of these kinases are elevated in some rhabdomyosarcoma tissues compared to normal tissues. Phosphorylation levels of receptor and non-receptor tyrosine kinases are elevated between 26 and 68% in alveolar rhabdomyosarcoma and between 24 and 71% in embryonal rhabdomyosarcoma, respectively, compared to normal tissues. In addition, phosphorylation levels of mTOR and its downstream targets, p70S6K, S6, and 4EBP1, are increased between 50 and 72% in both subtypes of rhabdomyosarcoma. Further, phosphorylation levels of PKCalpha, PKCdelta, PKCtheta, and PKCzeta/lambda are upregulated between 57 and 69% in alveolar rhabdomyosarcoma and between 43 and 72% in embryonal rhabdomyosarcoma. This is the first report to create a phosphorylation profile of tyrosine and serine/threonine kinases involved in the mTOR and PKC pathways of alveolar and embryonal rhabdomyosarcoma. These protein kinases may play roles in the development or tumor progression of rhabdomyosarcomas and thus may serve as novel targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17585318     DOI: 10.1038/modpathol.3800834

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  22 in total

1.  Diminished met signaling in podocytes contributes to the development of podocytopenia in transplant glomerulopathy.

Authors:  Putri A Agustian; Mario Schiffer; Wilfried Gwinner; Irini Schäfer; Katharina Theophile; Friedrich Modde; Clemens L Bockmeyer; Jana Traeder; Ulrich Lehmann; Anika Grosshennig; Hans H Kreipe; Verena Bröcker; Jan U Becker
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.

Authors:  Suman Malempati; Douglas S Hawkins
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

3.  In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.

Authors:  Judith Niesen; Hannes Brehm; Christoph Stein; Nina Berges; Alessa Pardo; Rainer Fischer; Andre Ten Haaf; Stefan Gattenlöhner; Mehmet K Tur; Stefan Barth
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-30       Impact factor: 4.553

4.  Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Authors:  Leo Mascarenhas; Yueh-Yun Chi; Pooja Hingorani; James R Anderson; Elizabeth R Lyden; David A Rodeberg; Daniel J Indelicato; Simon C Kao; Roshni Dasgupta; Sheri L Spunt; William H Meyer; Douglas S Hawkins
Journal:  J Clin Oncol       Date:  2019-09-12       Impact factor: 44.544

5.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Authors:  Jack F Shern; Li Chen; Juliann Chmielecki; Jun S Wei; Rajesh Patidar; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Jianjun Wang; Young K Song; Catherine Tolman; Laura Hurd; Hongling Liao; Shile Zhang; Dominik Bogen; Andrew S Brohl; Sivasish Sindiri; Daniel Catchpoole; Thomas Badgett; Gad Getz; Jaume Mora; James R Anderson; Stephen X Skapek; Frederic G Barr; Matthew Meyerson; Douglas S Hawkins; Javed Khan
Journal:  Cancer Discov       Date:  2014-01-23       Impact factor: 39.397

Review 6.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.

Authors:  Douglas S Hawkins; Sheri L Spunt; Stephen X Skapek
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

7.  SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer.

Authors:  Guoqiang Li; Weimin Ci; Subhradip Karmakar; Ke Chen; Ruby Dhar; Zhixiang Fan; Zhongqiang Guo; Jing Zhang; Yuwen Ke; Lu Wang; Min Zhuang; Shengdi Hu; Xuesong Li; Liqun Zhou; Xianghong Li; Matthew F Calabrese; Edmond R Watson; Sandip M Prasad; Carrie Rinker-Schaeffer; Scott E Eggener; Thomas Stricker; Yong Tian; Brenda A Schulman; Jiang Liu; Kevin P White
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

8.  Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.

Authors:  Kaiji Hu; Cathy Lee; Dexin Qiu; Abbas Fotovati; Alastair Davies; Samah Abu-Ali; Daniel Wai; Elizabeth R Lawlor; Timothy J Triche; Catherine J Pallen; Sandra E Dunn
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

9.  Expression of protein kinase C family in human hepatocellular carcinoma.

Authors:  Hsiu-Chin Lu; Fen-Pi Chou; Kun-Tu Yeh; Ya-Sian Chang; Nicholas C Hsu; Jan-Gowth Chang
Journal:  Pathol Oncol Res       Date:  2009-12-01       Impact factor: 3.201

10.  An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma.

Authors:  Jinu Abraham; Ying Xuan Chua; Jason M Glover; Jeffrey W Tyner; Marc M Loriaux; Aoife Kilcoyne; Francis J Giles; Laura D Nelon; Jennifer S Carew; Yongjian Ouyang; Joel E Michalek; Ranadip Pal; Brian J Druker; Brian P Rubin; Charles Keller
Journal:  Biochem Biophys Res Commun       Date:  2012-08-30       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.